This study is for the treatment of stage III non-small cell lung cancer

Primary disease category: Cancer

Secondary disease categories: Cancer, Lung Cancer

Sponsor: Southwest Oncology Group

Protocol number: S1206

Projected enrollment dates: October 2013 to December 2016

Official study title: S1206: A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)